---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343421"
form_type: "8-K"
ticker: "COAG"
cik: "0002114044"
company_name: "Hemab Therapeutics Holdings, Inc."
filed_at: "2026-08-11T11:11:07+00:00"
generated_at: "2026-08-11T11:15:21.266669+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hemab Q2 net loss $24.2M; FDA clears sutacimig Phase 3 in Glanzmann thrombasthenia

## Summary
- Net loss $24.2M ($0.80/share) vs $12.2M ($12.91/share) YoY; cash $457.5M, runway into 2029.
- FDA endorsed sutacimig data package for Phase 3 pivotal trial in GT; initiation planned 2H 2026.
- HMB-002 proof-of-mechanism: ≥2.4-fold VWF/FVIII increase; 8/9 patients zero treated bleeds post-dose.
- Unveiled HMB-003, novel peptide plasmin inhibitor for heavy menstrual bleeding; FIH trials 2H 2026.
- R&D expense $20.3M vs $12.9M; G&A $5.7M vs $3.2M YoY.

## SEC filing metadata
- accession: 0001193125-26-343421
- form_type: 8-K
- ticker: COAG
- cik: 0002114044
- company_name: Hemab Therapeutics Holdings, Inc.
- filed_at: 2026-08-11T11:11:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/0001193125-26-343421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/d180684d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343421
- JSON: https://secwatch.observer/filing/0001193125-26-343421.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343421.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.